Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind trial of ILB versus riluzole in ALS
2024-513927-18-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ilb in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Change in ALSFRS-R score at week 24. Planned start Apr 2025; status: authorised.
02
Drugs
ilb
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2024-513927-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513927-18-00.